Table 4.

Associations between listing of CKD on problem list with guideline-driven processes of care^a

	Outcome	Model 1	Model 2
Problem List CKD	Albuminuria test ordered	Odds Ratio	Odds Ratio
	N (%)	(95% C.I.)	(95% C.I.)
No = 932	288 (30%)	Ref	Ref
Yes = 679	472 (57%)	2.94 (2.39–3.62) †	2.83 (2.17–3.70) †
Problem List CKD	Parathyroid hormone test ordered
No = 932	109 (12%)	Ref	Ref
Yes = 679	400 (49%)	6.94 (5.40–8.92) †	5.03 (3.87–6.54) †
Problem List CKD	Phosphorus test ordered
No = 932	484 (51%)	Ref	Ref
Yes = 679	601 (73%)	2.24 (1.81–2.77) †	1.60 (1.27–2.01) †
Problem List CKD	Vitamin D test ordered
No = 932	446 47%	Ref	Ref
Yes = 679	573 70%	2.66 (2.16–3.27) †	2.35 (1.88–2.93) †
Problem List CKD	ACE/ARB prescription
No = 932	543 (57%)	Ref	Ref
Yes = 679	570 (69%)	1.63 (1.32–2.01) †	1.21 (0.94–1.55) †
Problem List CKD	Statin prescription
No = 932	565 (60%)	Ref	Ref
Yes = 679	600 (73%)	1.91 (1.53–2.37) †	1.56 (1.21–2.02) †

^aCharacteristics of patients included in process of care analyes, based on data from 01/01/2014 to 12/31/2015

Model 1 includes age, sex, race, and ethnicity

Model 2 adds each patient’s earliest 2nd qualifying eGFR (15–59.999 mL/min/1.73 m2) and comorbidities (diabetes mellitus, cerebrovascular disease, congestive heart failure, hypertension, and coronary artery disease)

^† = p < 0.05